Overexpression of pS6 has been associated with sensitivity to inhibitors of mTOR in previous studies, and are more likely to be expressed in metastases, suggestive of a poorer prognosis in RCC, in line with our findings (CSS with HR 8.63, CI 1.78–41.91, p = 0.008) (Table 3). The gene discussed is MTOR; the disease is renal cell carcinoma.